A single-center,observational cohort study to evaluate the effectiveness and safety of perampanel monotherapy in adults with focal seizures

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300074575

Enrollment

Unknown

Registered

2023-08-10

Start date

2021-12-15

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy

Interventions

Case series:Null

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Eligible patients were =18 years of age with a diagnosis of FOS according to the 2017 ILAE Classification of Epileptic Seizures. All patients were not under ASM treatment at the time of enrollment, or had uncontrolled seizures under current treatment and could receive perampanel before conversion to perampanel monotherapy.

Exclusion criteria

Exclusion criteria: people who were sensitive to the study drugs or its ingredients, or who were considered not sutible for this study by the investigator were excluded.

Design outcomes

Primary

Measure	Time frame
seizure freedom rate;	—

Secondary

Measure	Time frame
50% responder rate;retention;Safety;	—

Countries

China

Contacts

Public ContactRui Zhang

Nanjing Brain Hospital

neurosurgeonzr@njmu.edu.cn+86 25 8229 6557

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026